89 related articles for article (PubMed ID: 38538756)
21. Association of immune cell traits with Parkinson's disease: a Mendelian randomization study.
Song Z; Li W; Han Y; Xu Y; Ding H; Wang Y
Front Aging Neurosci; 2024; 16():1340110. PubMed ID: 38455666
[TBL] [Abstract][Full Text] [Related]
22. Causal role of immune cells in schizophrenia: Mendelian randomization (MR) study.
Wang C; Zhu D; Zhang D; Zuo X; Yao L; Liu T; Ge X; He C; Zhou Y; Shen Z
BMC Psychiatry; 2023 Aug; 23(1):590. PubMed ID: 37582716
[TBL] [Abstract][Full Text] [Related]
23. CD33 polymorphisms and Parkinson's disease Parkinson's disease in northern Chinese Han population: A case-control study.
Tian Q; Sun X; Li C; Yang Y; Hou B; Xie A
Neurosci Lett; 2023 Aug; 812():137400. PubMed ID: 37479176
[TBL] [Abstract][Full Text] [Related]
24. GSDMD in peripheral myeloid cells regulates microglial immune training and neuroinflammation in Parkinson's disease.
Wang B; Ma Y; Li S; Yao H; Gu M; Liu Y; Xue Y; Ding J; Ma C; Yang S; Hu G
Acta Pharm Sin B; 2023 Jun; 13(6):2663-2679. PubMed ID: 37425058
[TBL] [Abstract][Full Text] [Related]
25. Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease.
Schonhoff AM; Figge DA; Williams GP; Jurkuvenaite A; Gallups NJ; Childers GM; Webster JM; Standaert DG; Goldman JE; Harms AS
Nat Commun; 2023 Jun; 14(1):3754. PubMed ID: 37365181
[TBL] [Abstract][Full Text] [Related]
26. Integrative multilevel exploration of the mechanism by which Er-Zhi-Wan alleviates the Parkinson's disease (PD)-like phenotype in the MPTP-induced PD mouse model.
Pan B; Niu B; He Y; Zhou C; Xia C
Biomed Pharmacother; 2023 Sep; 165():115021. PubMed ID: 37348406
[TBL] [Abstract][Full Text] [Related]
27. Identification of potential inhibitors of tropomyosin receptor kinase B targeting CNS-related disorders and cancers.
Hakami MA; Alotaibi BS; Hazazi A; Shafie A; Alsaiari AA; Ashour AA; Anjum F
J Biomol Struct Dyn; 2024 Apr; 42(6):2965-2975. PubMed ID: 37184150
[TBL] [Abstract][Full Text] [Related]
28. Exploring causal correlations between inflammatory cytokines and systemic lupus erythematosus: A Mendelian randomization.
Xiang M; Wang Y; Gao Z; Wang J; Chen Q; Sun Z; Liang J; Xu J
Front Immunol; 2022; 13():985729. PubMed ID: 36741410
[TBL] [Abstract][Full Text] [Related]
29. Identifying crosstalk genetic biomarkers linking a neurodegenerative disease, Parkinson's disease, and periodontitis using integrated bioinformatics analyses.
Hu S; Li S; Ning W; Huang X; Liu X; Deng Y; Franceschi D; Ogbuehi AC; Lethaus B; Savkovic V; Li H; Gaus S; Zimmerer R; Ziebolz D; Schmalz G; Huang S
Front Aging Neurosci; 2022; 14():1032401. PubMed ID: 36545026
[TBL] [Abstract][Full Text] [Related]
30. Natural killer cells-related immune traits and amyotrophic lateral sclerosis: A Mendelian randomization study.
Gong Z; Liu Y; Ding F; Ba L; Zhang M
Front Neurosci; 2022; 16():981371. PubMed ID: 36248644
[TBL] [Abstract][Full Text] [Related]
31. Stroke genetics informs drug discovery and risk prediction across ancestries.
Mishra A; Malik R; Hachiya T; Jürgenson T; Namba S; Posner DC; Kamanu FK; Koido M; Le Grand Q; Shi M; He Y; Georgakis MK; Caro I; Krebs K; Liaw YC; Vaura FC; Lin K; Winsvold BS; Srinivasasainagendra V; Parodi L; Bae HJ; Chauhan G; Chong MR; Tomppo L; Akinyemi R; Roshchupkin GV; Habib N; Jee YH; Thomassen JQ; Abedi V; Cárcel-Márquez J; Nygaard M; Leonard HL; Yang C; Yonova-Doing E; Knol MJ; Lewis AJ; Judy RL; Ago T; Amouyel P; Armstrong ND; Bakker MK; Bartz TM; Bennett DA; Bis JC; Bordes C; Børte S; Cain A; Ridker PM; Cho K; Chen Z; Cruchaga C; Cole JW; de Jager PL; de Cid R; Endres M; Ferreira LE; Geerlings MI; Gasca NC; Gudnason V; Hata J; He J; Heath AK; Ho YL; Havulinna AS; Hopewell JC; Hyacinth HI; Inouye M; Jacob MA; Jeon CE; Jern C; Kamouchi M; Keene KL; Kitazono T; Kittner SJ; Konuma T; Kumar A; Lacaze P; Launer LJ; Lee KJ; Lepik K; Li J; Li L; Manichaikul A; Markus HS; Marston NA; Meitinger T; Mitchell BD; Montellano FA; Morisaki T; Mosley TH; Nalls MA; Nordestgaard BG; O'Donnell MJ; Okada Y; Onland-Moret NC; Ovbiagele B; Peters A; Psaty BM; Rich SS; Rosand J; Sabatine MS; Sacco RL; Saleheen D; Sandset EC; Salomaa V; Sargurupremraj M; Sasaki M; Satizabal CL; Schmidt CO; Shimizu A; Smith NL; Sloane KL; Sutoh Y; Sun YV; Tanno K; Tiedt S; Tatlisumak T; Torres-Aguila NP; Tiwari HK; Trégouët DA; Trompet S; Tuladhar AM; Tybjærg-Hansen A; van Vugt M; Vibo R; Verma SS; Wiggins KL; Wennberg P; Woo D; Wilson PWF; Xu H; Yang Q; Yoon K; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Millwood IY; Gieger C; Ninomiya T; Grabe HJ; Jukema JW; Rissanen IL; Strbian D; Kim YJ; Chen PH; Mayerhofer E; Howson JMM; Irvin MR; Adams H; Wassertheil-Smoller S; Christensen K; Ikram MA; Rundek T; Worrall BB; Lathrop GM; Riaz M; Simonsick EM; Kõrv J; França PHC; Zand R; Prasad K; Frikke-Schmidt R; de Leeuw FE; Liman T; Haeusler KG; Ruigrok YM; Heuschmann PU; Longstreth WT; Jung KJ; Bastarache L; Paré G; Damrauer SM; Chasman DI; Rotter JI; Anderson CD; Zwart JA; Niiranen TJ; Fornage M; Liaw YP; Seshadri S; Fernández-Cadenas I; Walters RG; Ruff CT; Owolabi MO; Huffman JE; Milani L; Kamatani Y; Dichgans M; Debette S
Nature; 2022 Nov; 611(7934):115-123. PubMed ID: 36180795
[TBL] [Abstract][Full Text] [Related]
32. Neuroinflammation and Parkinson's Disease-From Neurodegeneration to Therapeutic Opportunities.
Araújo B; Caridade-Silva R; Soares-Guedes C; Martins-Macedo J; Gomes ED; Monteiro S; Teixeira FG
Cells; 2022 Sep; 11(18):. PubMed ID: 36139483
[TBL] [Abstract][Full Text] [Related]
33. Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease.
Abdelmoaty MM; Machhi J; Yeapuri P; Shahjin F; Kumar V; Olson KE; Mosley RL; Gendelman HE
Clin Transl Med; 2022 Jul; 12(7):e958. PubMed ID: 35802825
[TBL] [Abstract][Full Text] [Related]
34. Inflammation and immune dysfunction in Parkinson disease.
Tansey MG; Wallings RL; Houser MC; Herrick MK; Keating CE; Joers V
Nat Rev Immunol; 2022 Nov; 22(11):657-673. PubMed ID: 35246670
[TBL] [Abstract][Full Text] [Related]
35. Tracking Innate Immune Activation in a Mouse Model of Parkinson's Disease Using TREM1 and TSPO PET Tracers.
Lucot KL; Stevens MY; Bonham TA; Azevedo EC; Chaney AM; Webber ED; Jain P; Klockow JL; Jackson IM; Carlson ML; Graves EE; Montine TJ; James ML
J Nucl Med; 2022 Oct; 63(10):1570-1578. PubMed ID: 35177426
[TBL] [Abstract][Full Text] [Related]
36. The neuroinflammatory role of glucocerebrosidase in Parkinson's disease.
Bo RX; Li YY; Zhou TT; Chen NH; Yuan YH
Neuropharmacology; 2022 Apr; 207():108964. PubMed ID: 35065083
[TBL] [Abstract][Full Text] [Related]
37. Neuroprotective Effect of Ceftriaxone on MPTP-Induced Parkinson's Disease Mouse Model by Regulating Inflammation and Intestinal Microbiota.
Zhou X; Lu J; Wei K; Wei J; Tian P; Yue M; Wang Y; Hong D; Li F; Wang B; Chen T; Fang X
Oxid Med Cell Longev; 2021; 2021():9424582. PubMed ID: 34938384
[TBL] [Abstract][Full Text] [Related]
38. Mendelian Randomization.
Birney E
Cold Spring Harb Perspect Med; 2022 May; 12(4):. PubMed ID: 34872952
[TBL] [Abstract][Full Text] [Related]
39. Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease.
Olson KE; Namminga KL; Lu Y; Schwab AD; Thurston MJ; Abdelmoaty MM; Kumar V; Wojtkiewicz M; Obaro H; Santamaria P; Mosley RL; Gendelman HE
EBioMedicine; 2021 May; 67():103380. PubMed ID: 34000620
[TBL] [Abstract][Full Text] [Related]
40. Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson's disease.
Thome AD; Atassi F; Wang J; Faridar A; Zhao W; Thonhoff JR; Beers DR; Lai EC; Appel SH
NPJ Parkinsons Dis; 2021 May; 7(1):41. PubMed ID: 33986285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
